- Home
- CRGO vs GLSI Comparison
CRGO vs GLSI Comparison
Compare CRGO & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGO
- GLSI
- Stock Information
- Founded
- CRGO 2012
- GLSI 2006
- Country
- CRGO Spain
- GLSI United States
- Employees
- CRGO N/A
- GLSI N/A
- Industry
- CRGO Blank Checks
- GLSI Biotechnology: Pharmaceutical Preparations
- Sector
- CRGO Finance
- GLSI Health Care
- Exchange
- CRGO Nasdaq
- GLSI Nasdaq
- Market Cap
- CRGO 165.6M
- GLSI 149.5M
- IPO Year
- CRGO N/A
- GLSI 2020
- Fundamental
- Price
- CRGO $3.01
- GLSI $11.23
- Analyst Decision
- CRGO
- GLSI Strong Buy
- Analyst Count
- CRGO 0
- GLSI 1
- Target Price
- CRGO N/A
- GLSI $39.00
- AVG Volume (30 Days)
- CRGO 82.6K
- GLSI 54.0K
- Earning Date
- CRGO 08-18-2025
- GLSI 08-14-2025
- Dividend Yield
- CRGO N/A
- GLSI N/A
- EPS Growth
- CRGO N/A
- GLSI N/A
- EPS
- CRGO N/A
- GLSI N/A
- Revenue
- CRGO $27,155,000.00
- GLSI N/A
- Revenue This Year
- CRGO $27.56
- GLSI N/A
- Revenue Next Year
- CRGO $24.45
- GLSI N/A
- P/E Ratio
- CRGO N/A
- GLSI N/A
- Revenue Growth
- CRGO 27.02
- GLSI N/A
- 52 Week Low
- CRGO $1.27
- GLSI $8.06
- 52 Week High
- CRGO $4.42
- GLSI $15.50
- Technical
- Relative Strength Index (RSI)
- CRGO 42.62
- GLSI 46.72
- Support Level
- CRGO $3.15
- GLSI $11.12
- Resistance Level
- CRGO $3.24
- GLSI $13.00
- Average True Range (ATR)
- CRGO 0.18
- GLSI 0.63
- MACD
- CRGO -0.05
- GLSI -0.06
- Stochastic Oscillator
- CRGO 0.00
- GLSI 26.56
About CRGO Freightos Limited Ordinary shares
Freightos Ltd operates as a vendor-neutral booking and payment platform for international freight. Its platform supports supply chain efficiency and agility by enabling real-time procurement of ocean and air shipping across more than ten thousand importers/exporters. forwarders, and dozens of airlines and ocean carriers. WebCargo by Freightos is a freight platform connecting carriers and forwarders in particular an air cargo eBooking platform. Freightos.com is a digital international freight marketplace for importers and exporters for instant pricing, booking, and shipment management. The company operates in two segments-Platform segment and Solutions segment. Geographically, the company operates in Europe, Hong Kong, United States which is majority revenue generator and others.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.